Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 19/20 | 0.73 |
| ▸ | CYP2C9 | P11712 | 12/20 | 0.73 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.73 |
| ▸ | BUB1 | O43683 | 1/20 | 0.71 |
| ▸ | PRKACG | P22612 | 1/20 | 0.71 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.71 |
| ▸ | ACSL5 | Q9ULC5 | 1/20 | 0.71 |
| ▸ | STK24 | Q9Y6E0 | 1/20 | 0.71 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3412151 | 0.94 | MAPK14 (0.74) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL3535883 | 0.93 | MAPK14 (0.73) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL30335917 | 0.91 | MAPK14 (0.70) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL3407001 | 0.91 | MAPK14 (0.70) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL3426681 | 0.90 | MAPK14 (0.71) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL3537400 | 0.90 | MAPK14 (0.71) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL3406811 | 0.90 | MAPK14 (0.71) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL3427110 | 0.90 | MAPK14 (0.70) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL27598541 | 0.90 | MAPK14 (0.59) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL3405633 | 0.89 | MAPK14 (0.75) | MAPK14CYP2C9MAPK11BUB1PRKACG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2258687-B1 | Nicotinamide derivates useful as P38 inhibitors | GLAXOSMITHKLINE LLC (US) | 2012-12-26 | — | — | EP | disclosed |
| EP-2258687-A1 | Nicotinamide derivates useful as P38 inhibitors | Glaxosmithkline LLC (US) | 2010-12-08 | — | — | EP | disclosed |
| US-7709506-B2 | Nicotinamide derivatives useful as p38 inhibitors | GLAXOSMITHKLINE LLC (US) | 2010-05-04 | — | — | US | disclosed |
| EP-1864975-A2 | Novel compounds | SmithKline Beecham Corporation (US) | 2007-12-12 | — | — | EP | disclosed |
| EP-1474395-B1 | NICOTINAMIDE DERIVATES USEFUL AS P38 INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2007-10-17 | — | — | EP | disclosed |
| US-7125898-B2 | Nicotinamide derivatives useful as p38 inhibitors. | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-24 | — | — | US | disclosed |
| US-20050176964-A1 | Nicotinamide derivatives useful as p38 inhibitors | GLAXOSMITHKLINE LLC | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176964-A1 | Nicotinamide derivatives useful as p38 inhibitors | MAPK1, MAPK7, MAPK6 | MAPK14 10/4885CYP2C9 2948/4885MAPK11 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.